Mesenchymal stem cell‐derived extracellular vesicles reduce senescence and extend health span in mouse models of aging. Issue 4 (16th March 2021)

• Record Type: Journal Article
• Authors: Dorronsoro, Akaitz; Santiago, Fernando E.; Grassi, Diego; Zhang, Tianpeng; Lai, Ruenn Chai; McGowan, Sara J.; Angelini, Luise; Lavasani, Mitra; Corbo, Lana; Lu, Aiping; Brooks, Robert W.; Garcia‐Contreras, Marta; Stolz, Donna B.; Amelio, Antonio; Boregowda, Siddaraju V.; Fallahi, Mohammad; Reich, Adrian; Ricordi, Camillo; Phinney, Donald G.; Huard, Johnny; Lim, Sai Kiang; Niedernhofer, Laura J.; Robbins, Paul D.
• Is Part Of: Aging cell. Volume 20:Issue 4(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-03-16
• Subjects: aging -- extracellular vesicles -- mesenchymal stem cells -- senescence -- stem cells; Cells -- Aging -- Periodicals; 571.8783605
• DOI: 10.1111/acel.13337
• Languages: English
• ISSNs: 1474-9718

Abstract

Abstract: Aging drives progressive loss of the ability of tissues to recover from stress, partly through loss of somatic stem cell function and increased senescent burden. We demonstrate that bone marrow‐derived mesenchymal stem cells (BM‐MSCs) rapidly senescence and become dysfunctional in culture. Injection of BM‐MSCs from young mice prolonged life span and health span, and conditioned media (CM) from young BM‐MSCs rescued the function of aged stem cells and senescent fibroblasts. Extracellular vesicles (EVs) from young BM‐MSC CM extended life span of Ercc1 −/− mice similarly to injection of young BM‐MSCs. Finally, treatment with EVs from MSCs generated from human ES cells reduced senescence in culture and in vivo, and improved health span. Thus, MSC EVs represent an effective and safe approach for conferring the therapeutic effects of adult stem cells, avoiding the risks of tumor development and donor cell rejection. These results demonstrate that MSC‐derived EVs are highly effective senotherapeutics, slowing the progression of aging, and diseases driven by cellular senescence. Abstract : Extracellular vesicles from young bone marrow‐derived mesenchymal stem cells (MSC) reduce markers of senescence in vitro. EVs derived from MSCs generated from human embryonic stem cells reduced expression of senescence markers in culture and in vivo in accelerated and naturally aged mice and improved measures of healthspan. This work demonstrates the senotherapeutic potential of extracellular vesicles in suppressing senescence‐driven age related disease.